ORGS vs. ACXP, STSA, NOVN, PPBT, RMTI, NERV, CKPT, FLGC, YMTX, and NLTX
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Acurx Pharmaceuticals (ACXP), Satsuma Pharmaceuticals (STSA), Novan (NOVN), Purple Biotech (PPBT), Rockwell Medical (RMTI), Minerva Neurosciences (NERV), Checkpoint Therapeutics (CKPT), Flora Growth (FLGC), Yumanity Therapeutics (YMTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis vs.
Orgenesis (NASDAQ:ORGS) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Acurx Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -35.18%. Orgenesis' return on equity of -41.99% beat Acurx Pharmaceuticals' return on equity.
Orgenesis has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals received 4 more outperform votes than Orgenesis when rated by MarketBeat users.
Orgenesis presently has a consensus price target of $6.00, indicating a potential upside of 412.82%. Acurx Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 374.58%. Given Orgenesis' higher probable upside, equities analysts plainly believe Orgenesis is more favorable than Acurx Pharmaceuticals.
In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.75 beat Orgenesis' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
16.8% of Orgenesis shares are held by institutional investors. Comparatively, 13.1% of Acurx Pharmaceuticals shares are held by institutional investors. 7.1% of Orgenesis shares are held by company insiders. Comparatively, 30.9% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Orgenesis beats Acurx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
